| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | myricetin | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | 0.0097 | 0.8 |
| mRNA | MG-132 | CTRPv2 | pan-cancer | AAC | -0.015 | 0.8 |
| mRNA | BRD-K48334597 | CTRPv2 | pan-cancer | AAC | -0.018 | 0.8 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.013 | 0.8 |
| mRNA | lovastatin | CTRPv2 | pan-cancer | AAC | 0.0093 | 0.8 |
| mRNA | SB-525334 | CTRPv2 | pan-cancer | AAC | 0.0091 | 0.8 |
| mRNA | BRD-K52037352 | CTRPv2 | pan-cancer | AAC | 0.0096 | 0.8 |
| mRNA | RITA | CTRPv2 | pan-cancer | AAC | -0.0076 | 0.9 |
| mRNA | SJ-172550 | CTRPv2 | pan-cancer | AAC | -0.0079 | 0.9 |